Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden

The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Marschollek, Paweł, Liszka, Karolina, Mielcarek-Siedziuk, Monika, Rybka, Blanka, Ryczan-Krawczyk, Renata, Panasiuk, Anna, Olejnik, Igor, Frączkiewicz, Jowita, Dachowska-Kałwak, Iwona, Mizia-Malarz, Agnieszka, Szczepański, Tomasz, Młynarski, Wojciech, Styczyński, Jan, Drabko, Katarzyna, Karolczyk, Grażyna, Gorczyńska, Ewa, Maciej Zaucha, Jan, Kałwak, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687755/
https://www.ncbi.nlm.nih.gov/pubmed/36428483
http://dx.doi.org/10.3390/biomedicines10112915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687755/
https://www.ncbi.nlm.nih.gov/pubmed/36428483
http://dx.doi.org/10.3390/biomedicines10112915

Ejemplares similares